Romison Rodrigues Mota – Director, ANVISA
Dr. Rodrigues Mota brings two decades of leadership experience within ANVISA, the Brazilian Health Regulatory Authority, where he has held multiple senior positions and now serves as a key architect…
Address: R. Cônego Felipe, 365 – Taquara – Rio de Janeiro – RJ CEP: 22713-010,Brazil
Tel: (21) 2159-2600
Laboratórios Bagó do Brasil is a pharmaceutical company outlined by its competencies of innovation and vision of the future. The company is an important part of Bagó Group founded in 1934, in Argentina. Established in the country in 2002, its founders have created an organization with a solid reputation based on ethics and commitment to quality.
The slogan “Ethics at the service of Heath” holds an special place on guiding the company’s actions, and so does the premium, the priority ingredient of the organization’s roles.
With a head office and a plant in the city of Rio de Janeiro, a distribution center in Brasilia and representatives in the major centers of consumption in the country, the company develops, distributes and commercializes innovative pharmaceutical products.
With an excellence and reliability standing, the company progressively attracts more attention and the trustiness of the country’s medical class, acquiring the respect of Brazilian’s consumers.
Keflex
Dr. Rodrigues Mota brings two decades of leadership experience within ANVISA, the Brazilian Health Regulatory Authority, where he has held multiple senior positions and now serves as a key architect…
Some of the top recent stories out of Latin America’s dynamic pharmaceutical and healthcare market. In Mexico, President Claudia Sheinbaum announced new investments from four leading Mexican pharmas totalling USD…
After a globe-trotting career that led him to diverse global affiliates, the long-term Takeda executive Rodrigo Rodriguez is going full circle. Returning to where he began his career at the…
A roundup of the biggest stories from Brazil’s pharma industry, including Teuto’s cannabis manufacturing deal with MediPharm; Eurofarma’s AI-based epilepsy joint venture with SK Biopharmaceuticals; EMS’s increased stake in Hypera…
With the largest public healthcare system in the world, Latin America’s biggest pharma market, its leading regulatory body, and a huge and diverse population, Brazil is a strategic destination for…
For the second consecutive year, DIA Europe hosted a Latin America Town Hall, a panel discussion to foster collaboration and share updates from regulatory activities in Latin America and Europe,…
An overview of some of the biggest stories from Latin American pharma and healthcare, including Brazil’s rollout of dengue vaccines following a sharp increase in cases; the Brazilian regulatory agency…
A roundup of some of the latest stories from Latin American pharma and healthcare, including Sanfer’s acquisition of Columbia-based injectables manufacturer Vitalis; medicine shortages in Colombia, and Chile’s move towards…
Brazil’s ANVISA is commonly recognised as LatAm’s leading national medicines regulator and is defined by the Pan American Health Organization (PAHO) as a National Regulatory Authority of Regional Reference (NRAr) for medicines…
The latest pharma news from Brazil, including the partnership between Biophytis and Innovation Solutions Pharma; Merck’s 100 years in Brazil; Eurofarma’s USD 100 million biotech investment, and GSK’s green light…
A roundup of some of the latest news from Latin American pharma, including Acino’s acquisition of M8 Pharmaceuticals; AstraZeneca’s growth in Mexico; Neuraxpharm’s expansion into Brazil and Mexico, and Columbia’s…
The DIA Global Annual Meeting 2023 hosted DIA’s first regulatory Town Hall fully dedicated to one regulator from Latin America, as leadership from Brazil’s Health Regulatory Agency, ANVISA, shared updates on the…
See our Cookie Privacy Policy Here
